S Ballesta1,2, R C Güerri-Fernández2,3,4, J J Chillarón5,6,7, A Güell2,8, S Herrera2,3, E Torres3, N G Ascoeta1, J A Flores Le-Roux1,2,4, A Díez2,3,4. 1. Department of Endocrinology and Nutrition, Hospital del Mar, PasseigMarítim, 25-29, 08003, Barcelona, Spain. 2. Department of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain. 3. Department of Internal Medicine, Hospital del Mar, Barcelona, Spain. 4. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 5. Department of Endocrinology and Nutrition, Hospital del Mar, PasseigMarítim, 25-29, 08003, Barcelona, Spain. JChillaron@parcdesalutmar.cat. 6. Department of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain. JChillaron@parcdesalutmar.cat. 7. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. JChillaron@parcdesalutmar.cat. 8. Department of Medicine, Universitat Pompeu Fabra, Barcelona, Spain.
Abstract
Diabetes mellitus is associated with a higher risk of fracture. In this study, we analysed the bone quality of premenopausal women with type 1 diabetes mellitus by microindentation. No differences in bone quality were identified between patients and healthy controls, suggesting that intensive insulin therapy can preserve bone health. PURPOSE: To compare the bone quality of women with type 1 diabetes mellitus (T1DM) and healthy controls, and to determine the relationship with bone mineral density (BMD). METHODS: This was a cross-sectional study of 45 premenopausal women with T1DM and 21 healthy controls, matched according to age and BMI. Clinical parameters, BMD and bone tissue mechanical properties (assessed using the bone material strength index [BMSi]) were evaluated in each group using microindentation. In T1DM patients, glycosylated haemoglobin (HbA1c), the number of hypoglycaemic events and the status of chronic complications were also analysed. RESULTS: No differences in BMSi or BMD between T1DM patients and healthy controls were identified. In the T1DM patients, the mean HbA1c was 7.52% ± 1.00% and the mean time elapsed since diagnosis was 22.6 ± 12.2 years. Eight patients (17.7%) met the criteria for metabolic syndrome (MetS), and microvascular complications were present in 12 patients (26.7%). Neither the number of features of MetS present nor the presence of microangiopathy was found to be associated with BMSi. CONCLUSIONS: T1DM premenopausal patients showed bone tissue properties comparable to those shown by controls. Further larger-scale studies should be conducted to confirm these results.
Diabetes mellitus is associated with a higher risk of fracture. In this study, we analysed the bone quality of premenopausal women with type 1 diabetes mellitus by microindentation. No differences in bone quality were identified between patients and healthy controls, suggesting that intensive insulin therapy can preserve bone health. PURPOSE: To compare the bone quality of women with type 1 diabetes mellitus (T1DM) and healthy controls, and to determine the relationship with bone mineral density (BMD). METHODS: This was a cross-sectional study of 45 premenopausal women with T1DM and 21 healthy controls, matched according to age and BMI. Clinical parameters, BMD and bone tissue mechanical properties (assessed using the bone material strength index [BMSi]) were evaluated in each group using microindentation. In T1DMpatients, glycosylated haemoglobin (HbA1c), the number of hypoglycaemic events and the status of chronic complications were also analysed. RESULTS: No differences in BMSi or BMD between T1DMpatients and healthy controls were identified. In the T1DMpatients, the mean HbA1c was 7.52% ± 1.00% and the mean time elapsed since diagnosis was 22.6 ± 12.2 years. Eight patients (17.7%) met the criteria for metabolic syndrome (MetS), and microvascular complications were present in 12 patients (26.7%). Neither the number of features of MetS present nor the presence of microangiopathy was found to be associated with BMSi. CONCLUSIONS:T1DM premenopausal patients showed bone tissue properties comparable to those shown by controls. Further larger-scale studies should be conducted to confirm these results.
Authors: Juan J Chillarón; Juana A Flores-Le-Roux; Alberto Goday; David Benaiges; María J Carrera; Jaume Puig; Juan F Cano-Pérez; Juan Pedro-Botet Journal: Rev Esp Cardiol Date: 2010-04 Impact factor: 4.753
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus Journal: Crit Pathw Cardiol Date: 2005-12
Authors: Joshua N Farr; Matthew T Drake; Shreyasee Amin; L Joseph Melton; Louise K McCready; Sundeep Khosla Journal: J Bone Miner Res Date: 2014-04 Impact factor: 6.741
Authors: Anna G Nilsson; Daniel Sundh; Lisa Johansson; Martin Nilsson; Dan Mellström; Robert Rudäng; Michail Zoulakis; Märit Wallander; Anna Darelid; Mattias Lorentzon Journal: J Bone Miner Res Date: 2017-01-18 Impact factor: 6.741
Authors: Unni Syversen; Mats Peder Mosti; Ida Maria Mynarek; Trude Seselie Jahr Vedal; Kristin Aasarød; Trude Basso; Janne E Reseland; Per Medbøe Thorsby; Bjorn O Asvold; Erik Fink Eriksen; Astrid Kamilla Stunes Journal: Endocr Connect Date: 2021-08-13 Impact factor: 3.335